Study #2022-1014
A phase 1 study of SGN-B7H4V in advanced solid tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
SGN-B7H4V, Pembrolizumab
Description
The purpose of the study is to test the safety of the medicine called SGN-B7H4V alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine. A side effect is anything a medicine does to the body besides treating the disease. This study is seeking for participants who either have cancer: * that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable), * has spread through the body (metastatic), or have some cancer left over after surgery. This study will have five parts. * Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. * Part C will use the amount found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers. * Part D will find out if and how much SGN-B7H4V can be given with pembrolizumab. * Part E will use the amount found in Part D to find out how safe SGN-B7H4V with pembrolizumab is and if it works to treat triple negative breast cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
Study phase:
Phase I
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-888-653-5845
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.